EXACT Therapeutics AS - EGM minutes
Exact Therapeutics AS Minutes From Extraordinary General Meeting – Appointment Of New Board Member
Oslo/London – 3 December 2021: Reference is made to the Notice of Extraordinary General Meeting of Exact Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX) published on 25 November 2021.
All proposed resolutions on the agenda were approved in accordance with the notice for the meeting. Please find the minutes of meeting linked below.
Minutes of the Extraordinary General Meeting on the 3rd of December 2021.
ENDS
For more information contact:
Dominic Moreland
CEO EXACT Therapeutics AS
Email: dominic@exact-tx.com
www.exact-tx.com
About EXACT Therapeutics AS
EXACT Therapeutics AS (“EXACT-Tx”) is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com
About ACT®
• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
• ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the Company is in oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.